Human FATE is a novel X-linked gene expressed in fetal and adult testis

Olesen, Christian Gammelgaard; Larsen, N. J.; Byskov, Anne Grete; Harboe, Theresa Larriba; Tommerup, Niels

doi:10.1016/s0303-7207(01)00666-9

Cited by 26 publications

(16 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[7][8][9] Accurate information on the actual protein expression is a prerequisite for the evaluation of its immunogenicity. For this aim, we have prepared the recombinant FATE/BJ-HCC-2 protein and produced its specific pAb, so as to analyze the FATE/BJ-HCC-2 antigen expression in HCC and other tumor samples.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, FATE/BJ-HCC-2 was coexpressed with SRY gene, which acts as a genetic switch that directs the development of the indifferent gonad from a female to a male pathway. 9 The FATE/BJ-HCC-2 protein may hence function in early testicular differentiation. The expression of FATE/BJ-HCC-2 may also be involved in tumorigenesis as its expression is regulated by steroidogenic factor (SF-1) and Wilms' tumor gene 1 (WT1), the molecules involved in the development of tumors.…”

Section: Discussionmentioning

confidence: 99%

“…2 FATE/BJ-HCC-2 was originally identified as a testis-specific gene and we have recently identified it as a CT antigen-encoding gene, which maps to chromosome Xq28. 8,9 According to the late classification of CT antigens, the FATE/BJ-HCC-2 is nominated as FATE/CT43. 7 We have demonstrated that FATE/BJ-HCC-2 mRNA is highly expressed in hepatocellular carcinoma (HCC) and not in normal tissues except testis by RT-PCR.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Immunohistochemical analysis of the expression of FATE/BJ-HCC-2 antigen in normal and malignant tissues

Yang

Dong

Qiao

et al. 2005

Laboratory Investigation

View full text Add to dashboard Cite

FATE/BJ-HCC-2 is a newly identified cancer/testis (CT) antigen, which was detected in tumor tissues and testis. As previous studies of FATE/BJ-HCC-2 expression pattern were mainly based on messenger RNA (mRNA) analysis, it is necessary to investigate its actual protein expression pattern in tumor tissues for the evaluation of its application value. In this study, we produced specific polyclonal antibody (pAb) to the recombinant FATE/ BJ-HCC-2 protein and analyzed the FATE/BJ-HCC-2 antigen expression in normal and malignant tissues by the immunohistochemical approach. The results showed that there was no detectable FATE/BJ-HCC-2 antigen expressed in normal tissues except testis. In hepatocellular carcinoma (HCC) tissues, the FATE/BJ-HCC-2 antigen was detected in 20% (7/35) specimens. All samples that expressed the FATE/BJ-HCC-2 antigen were of poorly or moderately differentiated HCC. The stained antigen was located in the cytoplasm and the staining pattern showed heterogeneity from focal to more than 40% of the tumor cells. The FATE/BJ-HCC-2 antigen was also expressed in other tumor tissues. The results of [ 3 H]thymidine incorporation showed that FATE/BJ-HCC-2 protein enhanced tumor cell proliferation after transfection of FATE/BJ-HCC-2 gene in HCC cell line (Po0.01). This effect could be specifically blocked by anti-FATE/BJ-HCC-2 pAb. Serological screening showed that the antibody specific to the FATE/BJ-HCC-2 antigen was detected in 7.7% (4/52) patients. Notably, the four positive patients bore poorly or moderately differentiated HCC. FATE/BJ-HCC-2 mRNA transcript was detected in the peripheral blood mononuclear cells (PBMCs) of 46.67% patients whose resected HCC tissue samples were positive for FATE/BJ-HCC-2 mRNA, which implicated tumor cell dissemination in blood circulation and may relate to the metastasis of HCC. Thus, FATE/BJ-HCC-2 may be a valuable candidate CT antigen for polyvalent vaccines in tumor immunotherapy and an assisting diagnostic marker for prognosis of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Immunohistochemical analysis of the expression of FATE/BJ-HCC-2 antigen in normal and malignant tissues

Yang

Dong

Qiao

et al. 2005

Laboratory Investigation

View full text Add to dashboard Cite

show abstract

“…FATE/BJ-HCC-2 was found to be coexpressed with SRY, which functions as a genetic switch that directs the development of the indifferent gonad from a female to a male pathway, in the 7-week-old fetal testis and might play a role in early testicular differentiation (Olesen et al, 2001). The expression of FATE/BJ-HCC-2 is regulated by steroidogenic factor (SF-1) and Wilms' tumour gene 1 (WT1) and involved in gamesomeness.…”

Section: Discussionmentioning

confidence: 99%

“…For the detection of mRNA expression of FATE/BJ-HCC-2, there were 16 different normal tissues of spleen, prostate, testis, ovary, small intestine, colon, peripheral blood, heart, lung, liver, adrenal gland, whole brain, kidney, pancreas, placenta, and skeletal muscle being tested by RT -PCR (Olesen et al, 2001), FATE/BJ-HCC-2 was strongly expressed in testis, and weakly detected in pancreatic tissue, but undetectable in other tissues. Quantification of gene expression revealed that the expression level of FATE/BJ-HCC-2 mRNA in the testis was five-fold higher than that in the pancreas.…”

Section: Expression In Normal Tissuesmentioning

confidence: 99%

Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients

et al. 2003

Br J Cancer

View full text Add to dashboard Cite

FATE and TPTE genes were originally reported to be specifically expressed in the adult testis. We searched for the databases of Unigene and serial analysis of gene expression (SAGE) implying that these two gene transcripts might also be expressed in tumours. Herein, we demonstrated that FATE and TPTE mRNA transcripts were expressed in different histological types of tumours and normal testis. Both are cancer-testis (CT) antigens and renamed as FATE/BJ-HCC-2 and TPTE/BJ-HCC-5, respectively. Comparison at nucleotide sequence, the FATE/BJ-HCC-2 cDNA, was identical to that of FATE, whereas the TPTE/BJ-HCC-5 was found to have two isoforms in both cancers and testis: one was identical in cDNA sequence to TPTE, encoding a protein of 551 amino acids, and the other variant lacked an exon of 54 bp, encoding a protein of 533 amino acids. The mRNA expression was analysed by RT -PCR and real-time PCR. FATE/BJ-HCC-2 mRNA was detected in 66% (41 out of 62) in hepatocellular carcinoma (HCC) samples and 21% (three out of 14) in colon cancer samples, whereas the TPTE/BJ-HCC-5 mRNA was detected in 39% (24 out of 62) and 36% (five out of 14) in HCC and non-small lung cancer samples, respectively. The recombinant proteins were prepared and the reactivity of allogenic sera to these two antigens was screened. The frequency of antibody response against FATE/BJ-HCC-2 and TPTE/BJ-HCC-5 proteins was 7.3% (three out of 41) and 25.0% (six out of 24), respectively, in HCC patients bearing respective gene transcripts. Therefore, FATE/BJ-HCC-2 and TPTE/BJ-HCC-5 are the novel CT antigens capable of eliciting antibody response in cancer patients.

show abstract

Proteomics in Endocrinology

Smit¹,

Romijn²

2003

Handbook of Proteomic Methods

View full text Add to dashboard Cite

Human FATE is a novel X-linked gene expressed in fetal and adult testis

Cited by 26 publications

References 30 publications

Immunohistochemical analysis of the expression of FATE/BJ-HCC-2 antigen in normal and malignant tissues

Immunohistochemical analysis of the expression of FATE/BJ-HCC-2 antigen in normal and malignant tissues

Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients

Proteomics in Endocrinology

Contact Info

Product

Resources

About